Abstract Search

ea0092op-09-01 | Oral Session 9: Thyroid Eye Disease | ETA2023

VRDN-001, a full antagonist antibody to IGF-1 receptor: in vitro pharmacology and phase 1/2 results in patients with thyroid eye disease (TED)

Douglas Raymond , Ugradar Shoaib , Turbin Roger , Cockerham Kimberly , Tang Rosa , Nijhawan Navdeep , Kossler Andrea , Boisvert Chantal , Lee Wendy , Yen Michael , Kaufman David , Yoon Michael , Bedian Vahe , Katz Barrett

Objectives: Antagonism of the IGF-1 receptor (IGF-1R) has been shown to reduce TED-related inflammation and proptosis. VRDN-001, a high-affinity antagonist antibody to IGF-1R, has distinct pharmacological properties that may enable differentiated dosing and better efficacy than observed with other antibodies. We assessed VRDN-001 in vitro pharmacology compared with teprotumumab and clinical proof of concept in a phase 1/2 randomized controlled trial (NCT05176639)....

0 shares

Endocrine Abstracts

VRDN-001, a full antagonist antibody to IGF-1 receptor: in vitro pharmacology and phase 1/2 results in patients with thyroid eye disease (TED)

BiosciAbstracts